{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:33:51Z","timestamp":1784136831062,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Prognostic predictors of immunotherapy in patients with advanced endometrial cancer remain unclear. The potential role of inflammatory predictors, including pretreatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and hemoglobin, albumin, lymphocyte and platelet scores, was investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between August 2018 and December 2023, 35 patients were retrospectively analyzed. Prognostic predictors were compared, and optimal cut-off values that exhibited the greatest discrimination for overall response, disease control, progression-free survival and overall survival were determined. Multivariate analysis was used to assess the prognostic significance of the predictors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The greatest discrimination for overall response, progression-free survival and overall survival included platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio and hemoglobin, albumin, lymphocyte and platelet; the areas under the curve were 0.638, 0.649 and 0.641, respectively. The precise cut-off values of neutrophil-to-lymphocyte ratio for progression-free survival and overall survival were 4.92 and 5.40, respectively. The lower neutrophil-to-lymphocyte ratio group had a significantly longer progression-free survival (P\u00a0=\u00a00.001, median survival; 4.0\u00a0months vs. 19\u00a0months) and longer overall survival (P\u00a0=\u00a00.002, median survival; 5.0\u00a0months vs. 21\u00a0months). Of the risk factors assessed, neutrophil-to-lymphocyte ratio (hazard ratio\u00a0=\u00a04.409; 95% CI\u00a0=\u00a01.10\u201317.64; P\u00a0=\u00a00.036) and regimen (hazard ratio\u00a0=\u00a05.559; 95% CI\u00a0=\u00a01.26\u201324.49; P\u00a0=\u00a00.023) were independently correlated with overall survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with advanced endometrial cancer, pretreatment neutrophil-to-lymphocyte ratio may be a prognostic predictor of those who would benefit from immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae123","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:50:41Z","timestamp":1725371441000},"page":"29-35","source":"Crossref","is-referenced-by-count":3,"title":["Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-6648","authenticated-orcid":false,"given":"Shintaro","family":"Yanazume","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1920-9405","authenticated-orcid":false,"given":"Shinichi","family":"Togami","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , 8-35-1 Sakuragaoka, Kagoshima 890-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"2025010815265626900_ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0107-3","article-title":"Novel technologies and emerging biomarkers for personalized cancer immunotherapy","volume":"4","author":"Yuan","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2025010815265626900_ref2","first-page":"CD003915","article-title":"Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma","volume":"2015","author":"Vale","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025010815265626900_ref3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: volume I - pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2025010815265626900_ref4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025010815265626900_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025010815265626900_ref6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/cas.14798","article-title":"Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors","volume":"112","author":"Akagi","year":"2021","journal-title":"Cancer Sci"},{"key":"2025010815265626900_ref7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"2025010815265626900_ref8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ijgc-2022-004026","article-title":"Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer","volume":"33","author":"Hill","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025010815265626900_ref9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10637-019-00845-w","article-title":"Germinal immunogenetics predict treatment outcome for PD-1\/PD-L1 checkpoint inhibitors","volume":"38","author":"Refae","year":"2020","journal-title":"Invest New Drugs"},{"key":"2025010815265626900_ref10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2023.12.007","article-title":"Pretreatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese Gynecologic Oncology Group 2043 exploratory data analysis","volume":"181","author":"Nishio","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025010815265626900_ref11","doi-asserted-by":"crossref","first-page":"68938","DOI":"10.18632\/oncotarget.20196","article-title":"Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"2025010815265626900_ref12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41598-018-19146-y","article-title":"Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy","volume":"8","author":"Peng","year":"2018","journal-title":"Sci Rep"},{"key":"2025010815265626900_ref13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007929","article-title":"Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from study 111\/KEYNOTE-146","volume":"12","author":"Makker","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025010815265626900_ref14","doi-asserted-by":"crossref","first-page":"111477","DOI":"10.1016\/j.intimp.2023.111477","article-title":"Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio","volume":"128","author":"Lin","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2025010815265626900_ref15","doi-asserted-by":"crossref","first-page":"602.e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"2025010815265626900_ref16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","article-title":"Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)","volume":"8","author":"Mandaliya","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2025010815265626900_ref17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"2025010815265626900_ref18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/0284186X.2021.1886323","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses","volume":"60","author":"Mjaess","year":"2021","journal-title":"Acta Oncol"},{"key":"2025010815265626900_ref19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jogoh.2018.08.016","article-title":"Platelet to lymphocyte and neutrophil to lymphocyte ratio as predictive indices of endometrial carcinoma: findings from a retrospective series of patients and meta-analysis","volume":"47","author":"Pergialiotis","year":"2018","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2025010815265626900_ref20","doi-asserted-by":"crossref","first-page":"734948","DOI":"10.3389\/fonc.2022.734948","article-title":"Prognostic significance of Pretreatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, or monocyte-to-lymphocyte ratio in endometrial neoplasms: a systematic review and meta-analysis","volume":"12","author":"Leng","year":"2022","journal-title":"Front Oncol"},{"key":"2025010815265626900_ref21","doi-asserted-by":"crossref","DOI":"10.1159\/000538288","article-title":"Can endometrial cytology identify patients who would benefit from immunotherapy?","volume":"68","author":"Yanazume","year":"2024","journal-title":"Acta Cytol"},{"key":"2025010815265626900_ref22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/cyt.13215","article-title":"Cytopathological features associated with POLE mutation in endometrial cancer","volume":"34","author":"Yanazume","year":"2023","journal-title":"Cytopathology"},{"key":"2025010815265626900_ref23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J Pathol"},{"key":"2025010815265626900_ref24","volume":"71","journal-title":"Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/1\/29\/59002038\/hyae123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/1\/29\/59002038\/hyae123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:27:09Z","timestamp":1736350029000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/1\/29\/7748233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae123","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,9,3]]}}}